Who is behind the molecules

AstraZeneca

Cambridge, United Kingdom

British-Swedish drugmaker whose diabetes portfolio has included exenatide (Byetta and Bydureon) and pramlintide (Symlin), which are older products. It is now developing investigational obesity drugs, including the oral GLP-1 receptor agonist elecoglipron, and in 2026 agreed a collaboration with CSPC Pharmaceuticals that includes a once-monthly dosing technology.

Boehringer Ingelheim

Ingelheim am Rhein, Germany

German pharmaceutical company developing survodutide, an investigational once-weekly glucagon/GLP-1 dual agonist for obesity and liver disease, under a licence from Zealand Pharma. Survodutide was not approved by any regulator we could verify as of 2026-09-29.

Eli Lilly

Indianapolis, Indiana, USA

American drugmaker that markets tirzepatide (as Mounjaro and Zepbound) and dulaglutide (as Trulicity), and holds rights to the oral GLP-1 drug orforglipron (Foundayo). Its pipeline also includes retatrutide and eloralintide, which are investigational. Figures below come from Lilly's filings with the U.S. Securities and Exchange Commission.

Novo Nordisk

Bagsværd, Denmark

Danish drugmaker that markets semaglutide (as Ozempic, Wegovy, Rybelsus and the Wegovy pill) and liraglutide (as Victoza and Saxenda) for type 2 diabetes and weight management. Its pipeline also includes cagrilintide (with semaglutide as CagriSema, for which the company listed a US regulatory decision as an upcoming milestone in its August 2026 report) and amycretin (called zenagamtide in its 2026 reports), which are investigational. Novo Nordisk files annual reports and quarterly announcements with the U.S. Securities and Exchange Commission, and its own figures are quoted below.

Pfizer

New York, New York, USA

American drugmaker that acquired Metsera in November 2025, a clinical-stage company developing medicines for obesity and cardiometabolic diseases; Metsera's candidates are investigational. In 2026 Pfizer also obtained rights to commercialise ecnoglutide in mainland China under an agreement with Sciwind Biosciences.

Roche

Basel, Switzerland

Swiss healthcare company whose obesity candidates include assets from its acquisition of Carmot Therapeutics (agreement announced in December 2023) and from a 2025 collaboration with Zealand Pharma. These candidates, including enicepatide (CT-388) and petrelintide, are investigational and not approved. None of the molecules currently in this atlas are listed as Roche products.

Amgen

Thousand Oaks, California, USA

American biotechnology company developing maridebart cafraglutide (MariTide), an investigational once-monthly obesity treatment that combines GLP-1 receptor activation with GIP receptor blocking. Amgen's second-quarter 2026 results release lists MariTide Phase 3 trials as ongoing or enrolling. It is not approved.

Innovent Biologics

Suzhou, China

Chinese biopharmaceutical company listed in Hong Kong (HKEX: 01801) with products in cancer, autoimmune, cardiovascular and metabolic, and eye diseases. In GLP-1 medicines, it holds an exclusive licence from Eli Lilly to develop and commercialise mazdutide, a dual glucagon and GLP-1 receptor agonist, in China, where the drug has been approved for weight management and for type 2 diabetes.

Palatin Technologies

Princeton, New Jersey, USA

US biotechnology company that develops melanocortin receptor drugs. It developed bremelanotide, which the US FDA has approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder, and sold its Vyleesi rights to Cosette Pharmaceuticals in December 2023. It has since reported a Phase 2 proof-of-concept trial of bremelanotide given together with tirzepatide in people with obesity, which is not an approved use.

Rhythm Pharmaceuticals

Boston, Massachusetts, USA

US biotechnology company focused on rare forms of obesity caused by disruption of the MC4R pathway, a brain hunger-and-energy signalling route. Its product IMCIVREE (setmelanotide) is an MC4R agonist. The company states it holds worldwide rights to it, and that it is approved or authorised in the United States, the European Union, Great Britain, Canada and other places for specific rare conditions.

Sciwind Biosciences

Hangzhou, China

Chinese biopharmaceutical company focused on weight management and metabolic disease. It developed ecnoglutide, a long-acting GLP-1 receptor agonist that the company describes as cAMP-biased, which China's regulator approved in 2026 for type 2 diabetes and for chronic weight management. Sciwind has licensing partnerships for the drug in China and in other regions.

Stealth BioTherapeutics

Needham, Massachusetts, USA

US biotechnology company working on mitochondria-targeted medicines. Its elamipretide is a peptide that the US FDA approved in September 2025 under the brand FORZINITY, under accelerated approval, for Barth syndrome. The company's current website says it is now named Mighty Therapeutics. It is not a GLP-1 developer.

Structure Therapeutics

South San Francisco, California, USA

Clinical-stage biotechnology company developing oral small-molecule (non-peptide) medicines that act on GPCR receptors. Its lead candidate, aleniglipron (GSBR-1290), is an investigational oral GLP-1 receptor agonist for obesity and is not approved anywhere. The company reports no product revenue.

Theratechnologies

Montreal, Canada

Canadian specialty biopharmaceutical company that markets tesamorelin in the United States as EGRIFTA SV and EGRIFTA WR. Tesamorelin is a growth hormone-releasing factor analogue that the US labels approve for reducing excess abdominal fat in adults with HIV and lipodystrophy; the labels state it is not indicated for weight loss management. In September 2025 an affiliate of Future Pak, LLC completed its acquisition of the company, which said its shares were expected to be delisted from the Toronto Stock Exchange and Nasdaq.

Viking Therapeutics

San Diego, California, USA

US clinical-stage biotechnology company whose lead candidate, VK2735, is a dual GLP-1 and GIP receptor agonist being developed in injected and oral forms for obesity. VK2735 is an investigational drug and is not approved anywhere. The company reports no product revenue.

Zealand Pharma

Copenhagen, Denmark

Danish biotechnology company that describes itself as focused on medicines for obesity and metabolic health. It co-develops petrelintide, an investigational amylin analogue, with Roche. It licensed survodutide, an investigational glucagon/GLP-1 dual agonist, to Boehringer Ingelheim and is eligible for royalties and milestone payments on it. Neither drug is approved.

Apotex

Toronto, Ontario, Canada

Canadian generic medicines company. Its parent, Apotex Health Corp., describes itself as Canada's largest pharmaceutical company and is listed on the Toronto Stock Exchange (TSX: APTX). In GLP-1s it has Health Canada approval for two generic semaglutide products, one referencing Ozempic and one referencing Wegovy, and a US FDA tentative approval for a generic semaglutide injection. Details below are as Apotex states them in its own releases.

Biocon

Bengaluru, India

Indian biopharmaceutical company (Biocon Limited) that makes generic and biosimilar medicines. In GLP-1s it sells generic liraglutide, the older GLP-1 drug behind Victoza and Saxenda, in the UK and, since 2026, in the US. It has also announced a licensing and supply agreement for semaglutide in Brazil. Biocon does not report GLP-1 revenue as a separate line in the releases cited here. Details below are as Biocon states them.

Dr. Reddy's Laboratories

Hyderabad, India

Indian pharmaceutical company listed in India and on the New York Stock Exchange. It makes generic semaglutide injection and launched it in India in March 2026 and in Canada in 2026. Its filings say it produces the active ingredient in-house. In July 2026 it disclosed that certain batches were out of specification because of an issue with the active ingredient, and that commercial supplies would be delayed. Statements below are the company's own, taken from its filings with the SEC.

Sandoz

Basel, Switzerland

Swiss generic and biosimilar medicines company. In GLP-1s it has a marketing authorisation for a generic semaglutide (a version of Ozempic) in Canada, holds commercial rights to a semaglutide product approved in Brazil that was developed by Adalvo, and has US FDA applications under review for an in-house generic tirzepatide. Its tirzepatide applications are under FDA review and are not approved. Details below are as Sandoz states them in its own media releases.

Hims & Hers Health

San Francisco, California, USA

American online health company. Its filings say it connects patients with licensed clinicians who can prescribe medicines when appropriate, with prescriptions filled by licensed pharmacies, across areas that include weight loss. It is not the maker of any approved GLP-1 drug. According to its filings, it began offering access to compounded injectable semaglutide in May 2024 and, in 2026, moved its US weight-loss offering towards branded GLP-1 medicines, with compounded versions offered on a limited scale. Compounded drugs are not FDA-approved. Figures and legal matters below are as the company reports them in its SEC filings.

Ro

New York, New York, USA

Privately held American direct-to-patient telehealth company. It describes itself as offering online clinician visits, labs and pharmacy services on one platform, founded in 2017. It is not the maker of any approved GLP-1 drug. Its press releases describe working with Eli Lilly and Novo Nordisk so that its patients can be prescribed their branded, FDA-approved obesity medicines. Ro is privately held, and none of the sources cited here gives a revenue figure. Facts below come from Ro's own press releases, cited as archived copies because ro.co blocks automated access.